SAN MATEO, Calif., May 16, 2024 (GLOBE NEWSWIRE) Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
A large Swedish cohort study finds a significant protective association between statin use and liver disease progression in adults with non-cirrhotic chronic liver disease.
Research: Potential new targets identified in non-alcoholic fatty liver disease webindia123.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webindia123.com Daily Mail and Mail on Sunday newspapers.
Researchers have uncovered a network of cell-to-cell communication driving scarring as liver disease advances, which could lead to novel drug targets for non-alcoholic fatty liver disease.